Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy for multiple myeloma: what happens years later?

NCT ID NCT05201781

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This study follows 295 multiple myeloma patients who previously received cilta-cel (a CAR-T cell therapy) to track long-term side effects. No new treatment is given. Researchers will monitor for new cancers, nerve disorders, autoimmune issues, and infections over time. The goal is to better understand the lasting safety of this therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cilta-cel (CAR-T cell therapy)
What this could lead to
If successful, this study will help doctors understand the long-term safety of cilta-cel, potentially improving monitoring and care for multiple myeloma patients.
What could go wrong
This is an observational follow-up study, not a new treatment trial. It cannot show whether cilta-cel works better than other options, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 295 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Jun 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study * Participants who have provided informed consent for this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    37 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barbara Ann Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • CHRU de Lille Hopital Claude Huriez

    RECRUITING

    Nord, 59037, France

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • Clinica Univ. de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • First Hospital, Zhejiang University Medical College

    ACTIVE_NOT_RECRUITING

    Hangzhou, 310003, China

  • Froedtert Memorial

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Fujian Medical University Union Hospital

    ACTIVE_NOT_RECRUITING

    Fuzhou, 350000, China

  • Hackensack University Medical Center

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Hopital Saint Louis

    RECRUITING

    Paris, 75010, France

  • Hosp Clinico Univ de Salamanca

    RECRUITING

    Salamanca, 37007, Spain

  • Indiana University

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Japanese Red Cross Medical Center

    ACTIVE_NOT_RECRUITING

    Shibuya City, 150-8935, Japan

  • Jiangsu Province Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, 210029, China

  • Kansas University Medical Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • Levine Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Mayo Clinic Cancer Center-Scottsdale

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Rochester

    RECRUITING

    Rochester, Minnesota, 55902, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

  • Mount Sinai Medical Center

    RECRUITING

    New York, New York, 10029, United States

  • Nagoya City University Hospital

    ACTIVE_NOT_RECRUITING

    Nagoya, 467 8602, Japan

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

    ACTIVE_NOT_RECRUITING

    Nanjing, 210008, China

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Peking University Third Hospital

    ACTIVE_NOT_RECRUITING

    Beijing, 100191, China

  • Roswell Park Cancer Institute

    RECRUITING

    Buffalo, New York, 14263, United States

  • Ruijin Hospital Shanghai Jiao Tong University

    ACTIVE_NOT_RECRUITING

    Shanghai, 200025, China

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08903, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Shanghai Changzheng Hospital

    ACTIVE_NOT_RECRUITING

    Shanghai, 200003, China

  • Shanghai Fourth People s Hospital

    ACTIVE_NOT_RECRUITING

    Shanghai, 200434, China

  • Stanford University Medical Center

    RECRUITING

    Stanford, California, 94305-5623, United States

  • Sun Yat-sen University Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Guangzhou, 510060, China

  • Tel Aviv Sourasky Medical Center

    RECRUITING

    Tel Aviv, 64239, Israel

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    ACTIVE_NOT_RECRUITING

    Xi'an, 710004, China

  • UZ Gent

    RECRUITING

    Ghent, 9000, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • University Medical Center Groningen

    RECRUITING

    Groningen, 9713 GZ, Netherlands

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • VU Medisch Centrum

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

  • Washington University School Of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

  • West China Hospital Si Chuan University

    ACTIVE_NOT_RECRUITING

    Chengdu, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.